Clinical Trials Logo

Ischemic Heart Disease clinical trials

View clinical trials related to Ischemic Heart Disease.

Filter by:

NCT ID: NCT03586492 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Coronary Flow Reserve (CFR) in Cardiovascular Risk Stratification

CFR-OR
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

CFR has been studied for few years using 82 Rubidium PET (positron emission tomography) /CT. CFR has shown to be correlated with cardiovascular events occurring in the 10 following years. CFR also helps to identify multivessel coronary disease. Few studies have shown the possibility to calculate CFR during myocardial perfusion SPECT on new ultrafast CZT cameras.

NCT ID: NCT03583320 Recruiting - Clinical trials for Coronary Artery Disease

Trial of Cardiac CT in Acute Chest Patients With Intermediate Level Initial High-sensitivity Cardiac Troponin

PROTECCT
Start date: January 12, 2018
Phase: N/A
Study type: Interventional

Patients who present to the emergency department (ED) with acute chest pain (ACP) possibly due to Coronary artery disease (CAD), with a normal heart tracing (ECG), need to have further troponin blood tests to confirm or exclude a heart attack. After initial troponin testing, a significant 50-85% of patients are said to be in an "observational zone" as one cannot confirm or exclude a diagnosis of a heart attack. Even after repeat blood testing, 22-33% remain in this "observational zone". These patients can be challenging to manage as they are not safe to be discharged home, but they also cannot be treated as a heart attack. This contributes to ED overcrowding and uncertainty in treatment plans.

NCT ID: NCT03577821 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Early Outcome of Total Arterial Revasclarization in IHD

Start date: July 1, 2018
Phase:
Study type: Observational

Complete arterial coronary artery bypass grafting (CABG) is a surgical option to improve long-term results in the treatment of coronary artery disease (CAD). The goal of coronary artery bypass operations is complete revascularization and there is an increasing interest toward complete arterial revascularization to achieve this goal because of high late failure of saphenous vein graft

NCT ID: NCT03567733 Not yet recruiting - Clinical trials for Coronary Artery Disease

Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study

SIERRA 75
Start date: June 30, 2018
Phase:
Study type: Observational [Patient Registry]

This prospective registry is intended to evaluate the safety and efficacy of the XIENCE Sierra stent.

NCT ID: NCT03563417 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Nordic Randomized Trial on the Prognostic Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions

NORDIC-CTO
Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Study design Prospective randomized open labeled multicenter study Hypotheses 1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events). 2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months. Inclusion Criteria - CTO in native coronary artery - Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging. - Age ≥18 yrs. - Target artery ≥ 2.5 mm Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into: Cohort A:Asymptomatic patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO Cohort B: Symptomatic patients (CCS class ≥ II and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO Exclusion criteria (for both cohort A and B) - NSTEMI or STEMI within 1 month - Coronary anatomy not suitable for CTO-procedure - Life expectancy < 2 years - Severe chronic pulmonary disease (FEV1 < 30 % of predicted value) - Contraindication to dual anti-platelet therapy - Pregnancy - eGFR < 20 mL/min/1.73 m2 Primary endpoint Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, myocardial infarction, clinically driven revascularization*), hospitalization for heart failure or incidence of malignant arrhythmias. *CCS class ≥ II and/or QoL score < 60. Same criteria used as for allocation to Cohort B Cohort B: SAQ Quality of Life Assessment after 6 months. Number of patients 1,500 Follow up time Cohort A: 5 years Cohort B: 6 months Detailed description

NCT ID: NCT03541109 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

A Polypill for Secondary Prevention of Ischemic Heart Disease

Start date: August 2018
Phase: Phase 3
Study type: Interventional

Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The most important aspect of CVD secondary prevention is adherence to guideline-indicated pharmacological therapy which globally remains low. In previous studies, a Polypill containing fixed dose combination of essential drugs have improved patient adherence to these drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness, and CVD recurrence in our setting will be assessed in this study. Participants hospitalized in three referral hospitals in Isfahan, Iran because of an acute coronary syndrome (ACS) or revascularization procedure (PCI or CABG) will be randomized to either receiving Polypill or four components of Polypill separately. Patient recruitment will be carried out at the time of patient discharge from the hospitals.

NCT ID: NCT03537586 Not yet recruiting - Myocardial Ischemia Clinical Trials

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Start date: June 29, 2018
Phase: N/A
Study type: Interventional

Among patients with stable ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40% of these patients. However, the mechanisms and optimal treatment of coronary microvascular dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized as mechanisms of microvascular dysfunction. Investigators plan to evaluate association between platelet activity, inflammation, and coronary microvascular dysfunction in stable women referred for coronary angiography, and to identify non-invasive correlates of coronary microvascular dysfunction in these patients.

NCT ID: NCT03531151 Recruiting - Heart Failure Clinical Trials

MRI of Myocardial Infarction

MRIMI
Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

Heart failure (HF) is an enormous health burden affecting approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia and requires immediate restoration of coronary blood flow to the affected myocardium. However, the success of reperfusion is partly limited by intramyocardial hemorrhage, which is the deposition of intravascular material into the myocardium. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling, risk of fatal arrhythmia, impaired systolic function and are hospitalized at a greater rate. Recent magnetic resonance imaging techniques have improved assessment of reperfusion injury, however, the association between MRI contrasts and reperfusion injury is highly unclear, and lacks specificity to IMH. Improved imaging of IMH and accurate knowledge about its spatial and temporal evolution may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for adverse ventricular remodeling. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic susceptibility of tissues and can target tissue iron. Therefore, the investigators hypothesize that MRI imaging of myocardial magnetic susceptibility can map hemorrhagic myocardium. The investigators will perform a longitudinal observational study in patients after reperfusion injury to validate these methods, compare the methods with conventional MR contrasts and develop MR methods for imaging humans.

NCT ID: NCT03523286 Not yet recruiting - Clinical trials for Ischemic Heart Disease

Real-time Automated Program for IDentification of VT Origin

RAPIDVTPilot
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

RAPID-VT Pilot is a single centre prospective cohort pilot study to assess the feasibility, safety and efficacy of catheter ablation of ventricular tachycardia (VT) guided by a novel real-time software to localize the origin of VT during the ablation procedure.

NCT ID: NCT03501303 Recruiting - Clinical trials for Ischemic Heart Disease

A Clinical Trial on No-touch Vein Graft (NT-graft) in Coronary Surgery

SWEDEGRAFT
Start date: April 20, 2018
Phase: N/A
Study type: Interventional

The primary objective in this study is to investigate if vein grafts harvested and implanted with the non-touch technique are superior to conventional vein graft technique with respect to mid-term patency, in patients undergoing CABG surgery.